Gilliam F Roosevelt, Singh Jagmeet P, Mullin Christopher M, McGuire Maureen, Chase Kellie J
Cardiology Associates of Northeast Arkansas, Jonesboro, AR, USA.
J Electrocardiol. 2007 Oct;40(4):336-42. doi: 10.1016/j.jelectrocard.2006.11.012. Epub 2007 Feb 22.
Cardiac resynchronization therapy devices provide effective therapy for heart failure. Heart rate variability (HRV) parameters in the device such as HRV footprint and SD of average 5-minute intrinsic R-R intervals (SDANN) are related to autonomic function and may be used to identify patients with a higher risk of mortality.
We examined the relationship between HRV and mortality in a prospective cohort study. The 842 patients (mean age, 67.7 +/- 11.2; 23.5 % female; New York Heart Association class III, 88.6%; class IV, 11.4%) included in the analysis were implanted with a cardiac resynchronization therapy with defibrillation device and had baseline HRV measurements available.
During a median of 11.6 months of follow-up, 7.8% (66/842) of patients died. Heart rate variability footprint and SDANN were significant predictors of mortality (all P < .05); patients with lower HRV values were at greater risk for death, compared with patients with higher HRV values. Heart rate variability changes over time tended to predict the risk of mortality in follow-up (P = nonsignificant); patients with low baseline HRV and small changes in HRV during the follow-up period were at the highest risk for death (7% mortality for SDANN and 8.9% for HRV footprint), and patients with high baseline HRV and large changes in HRV were at the lowest risk (1.5% mortality for SDANN and 2.4% for HRV footprint). Results were consistent when adjusted for age, sex, body mass index, and diastolic blood pressure.
Continuously measured device HRV parameters provide prognostic information about patient mortality that may be helpful for risk stratification.
心脏再同步治疗设备为心力衰竭提供了有效的治疗方法。该设备中的心率变异性(HRV)参数,如HRV足迹和平均5分钟固有R-R间期标准差(SDANN),与自主神经功能相关,可用于识别死亡风险较高的患者。
我们在一项前瞻性队列研究中检验了HRV与死亡率之间的关系。纳入分析的842例患者(平均年龄67.7±11.2岁;23.5%为女性;纽约心脏协会心功能分级III级占88.6%,IV级占11.4%)植入了带除颤功能的心脏再同步治疗设备,并进行了基线HRV测量。
在中位随访11.6个月期间,7.8%(66/842)的患者死亡。HRV足迹和SDANN是死亡率的显著预测指标(均P<0.05);与HRV值较高的患者相比,HRV值较低的患者死亡风险更高。HRV随时间的变化倾向于预测随访期间的死亡风险(P=无显著性);基线HRV低且随访期间HRV变化小的患者死亡风险最高(SDANN死亡率为7%,HRV足迹死亡率为8.9%),而基线HRV高且HRV变化大的患者死亡风险最低(SDANN死亡率为1.5%,HRV足迹死亡率为2.4%)。在对年龄、性别、体重指数和舒张压进行校正后,结果一致。
持续测量的设备HRV参数可提供有关患者死亡率的预后信息,这可能有助于进行风险分层。